CN106821973A - 一种棓丙酯注射液及其制备方法和应用 - Google Patents
一种棓丙酯注射液及其制备方法和应用 Download PDFInfo
- Publication number
- CN106821973A CN106821973A CN201710174463.3A CN201710174463A CN106821973A CN 106821973 A CN106821973 A CN 106821973A CN 201710174463 A CN201710174463 A CN 201710174463A CN 106821973 A CN106821973 A CN 106821973A
- Authority
- CN
- China
- Prior art keywords
- parenteral solution
- preparation
- injection
- adjusting agent
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003182 parenteral nutrition solution Substances 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 21
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000001301 oxygen Substances 0.000 claims abstract description 16
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 16
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000003002 pH adjusting agent Substances 0.000 claims abstract description 13
- 230000001954 sterilising effect Effects 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 11
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000008215 water for injection Substances 0.000 claims abstract description 10
- 239000003708 ampul Substances 0.000 claims abstract description 6
- 238000010926 purge Methods 0.000 claims abstract description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 239000008232 de-aerated water Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims description 2
- 206010034897 Phlebitis deep Diseases 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 description 19
- 235000006708 antioxidants Nutrition 0.000 description 18
- 239000000463 material Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000012467 final product Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000012535 impurity Substances 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- -1 30L propane diols Chemical class 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-N disulfurous acid Chemical compound OS(=O)S(O)(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710174463.3A CN106821973B (zh) | 2017-03-22 | 2017-03-22 | 一种棓丙酯注射液及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710174463.3A CN106821973B (zh) | 2017-03-22 | 2017-03-22 | 一种棓丙酯注射液及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106821973A true CN106821973A (zh) | 2017-06-13 |
CN106821973B CN106821973B (zh) | 2019-06-28 |
Family
ID=59129397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710174463.3A Active CN106821973B (zh) | 2017-03-22 | 2017-03-22 | 一种棓丙酯注射液及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106821973B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110680807A (zh) * | 2019-08-01 | 2020-01-14 | 广东健信制药股份有限公司 | 一种注射用棓丙酯的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1481787A (zh) * | 2003-07-29 | 2004-03-17 | 吉林市卓怡康纳制药有限公司 | 棓丙酯注射液及其制备方法 |
-
2017
- 2017-03-22 CN CN201710174463.3A patent/CN106821973B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1481787A (zh) * | 2003-07-29 | 2004-03-17 | 吉林市卓怡康纳制药有限公司 | 棓丙酯注射液及其制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110680807A (zh) * | 2019-08-01 | 2020-01-14 | 广东健信制药股份有限公司 | 一种注射用棓丙酯的制备方法 |
CN110680807B (zh) * | 2019-08-01 | 2021-07-13 | 广东健信制药股份有限公司 | 一种注射用棓丙酯的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN106821973B (zh) | 2019-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010132695A (ja) | 吸入用組成物 | |
CN102988291A (zh) | 一种氟比洛芬酯脂肪乳注射液组合物及其制备方法 | |
JP4861162B2 (ja) | 注射用パラセタモール液状製剤 | |
CN106692124A (zh) | 乙酰半胱氨酸药物组合物及其制备方法 | |
CN108938626A (zh) | 一种稳定性好和安全性高的卡络磺钠药物组合物及其制备方法和应用 | |
CN103340866B (zh) | 一种哌拉西林钠和他唑巴坦钠的药物组合物及其制备方法 | |
CN106821973B (zh) | 一种棓丙酯注射液及其制备方法和应用 | |
AU2010283717B2 (en) | Storage-stable formulation of paracetamol in aqueous solution | |
CN111870591B (zh) | 一种控制乙酰半胱氨酸溶液硫化氢含量的方法 | |
EP2672955A1 (en) | Storage-stable formulation of paracetamol in aqueous solution | |
EP3040067A1 (en) | Chlorogenic acid powder-injection and preparation method thereof | |
CN110455974B (zh) | 采用高效液相色谱法检测贝莎罗汀软胶囊杂质的方法 | |
CN114432240A (zh) | 一种稳定不刺激的酮咯酸氨丁三醇注射液及其制备方法 | |
CN102166185B (zh) | 等渗纳洛酮注射液及其制备方法 | |
CN107041868A (zh) | 一种稳定的奥硝唑注射液和s-奥硝唑注射液及其制备方法 | |
CN101791315A (zh) | 复方甘草酸单铵s药物组合物及其大容量注射剂制备方法 | |
CN109010290A (zh) | 一种乌司他丁冻干粉制剂的制备方法 | |
CN113521244B (zh) | 一种阿加曲班注射剂及其制备方法 | |
CN113398065A (zh) | 一种间苯三酚注射液的制备方法 | |
CN101322684A (zh) | 醋酸去氨加压素注射液处方及其制备工艺 | |
CN113876704A (zh) | 一种盐酸表柔比星注射液及其制备方法 | |
CN106943342B (zh) | 一种含有阿加曲班的药物组合物 | |
CN107356690B (zh) | 眼用凝胶剂中有关物质的分离与检测方法 | |
CN112156067A (zh) | 一种含有米力农的药物组合物及其制备方法 | |
CN114983935B (zh) | 一种缩宫素注射液及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 277000 Shandong province Zaozhuang Shengong high tech Industrial Development Zone, Road No. 369 Co-patentee after: Weizhi Pharmaceutical Co.,Ltd. Patentee after: SHANDONG VIWIT BAIKE PHARMACEUTICAL CO.,LTD. Address before: 277000 Shandong province Zaozhuang Shengong high tech Industrial Development Zone, Road No. 369 Co-patentee before: VIWIT PHARMACEUTICAL Co.,Ltd. Patentee before: SHANDONG VIWIT BAIKE PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Propylgallate injection, and preparation method and application of propylgallate injection Effective date of registration: 20200624 Granted publication date: 20190628 Pledgee: Rizhao Bank Co.,Ltd. Zaozhuang Tengzhou Branch Pledgor: SHANDONG VIWIT BAIKE PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980003484 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210902 Granted publication date: 20190628 Pledgee: Rizhao Bank Co.,Ltd. Zaozhuang Tengzhou Branch Pledgor: SHANDONG VIWIT BAIKE PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980003484 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Propyl gallate injection and its preparation method and Application Effective date of registration: 20210923 Granted publication date: 20190628 Pledgee: Zaozhuang Rural Commercial Bank Co.,Ltd. Gaoxin sub branch Pledgor: SHANDONG VIWIT BAIKE PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980009763 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220328 Granted publication date: 20190628 Pledgee: Zaozhuang Rural Commercial Bank Co.,Ltd. Gaoxin sub branch Pledgor: SHANDONG VIWIT BAIKE PHARMACEUTICAL CO.,LTD. Registration number: Y2021980009763 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
CP01 | Change in the name or title of a patent holder |
Address after: 277000 No. 369, Shengong Road, high tech Industrial Development Zone, Zaozhuang City, Shandong Province Patentee after: SHANDONG VIWIT BAIKE PHARMACEUTICAL CO.,LTD. Patentee after: Weizhi Pharmaceutical Co.,Ltd. Address before: 277000 No. 369, Shengong Road, high tech Industrial Development Zone, Zaozhuang City, Shandong Province Patentee before: SHANDONG VIWIT BAIKE PHARMACEUTICAL CO.,LTD. Patentee before: Weizhi Pharmaceutical Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |